Home » Akebia Completes Single-Dose Phase IIa Trial of Oral Anemia Drug
Akebia Completes Single-Dose Phase IIa Trial of Oral Anemia Drug
Akebia Therapeutics Inc. has successfully completed a Phase 2a trial of its orally administered anti-anemia drug for kidney disease patients.
MedCity News
MedCity News
Upcoming Events
-
07May
-
14May
-
30May